Incidence of Anxiety in Patients with Multiple Sclerosis (MS)
Keywords:Multiple Sclerosis (MS), anxiety, disease duration, age, disability
Objective: To investigate the (1) incidence of anxiety and (2) association of anxiety with disease duration, depression, and age in an outpatient Multiple Sclerosis (MS) Center.
Background: The incidence of anxiety varies in the literature but is estimated to affect 44.5% of people with MS. Anxiety can be a predictor of poor Quality of Life, especially relevant in progressive illnesses, such as MS. Though research has shown that patients newly diagnosed experience higher anxiety levels, the relationship between anxiety and disease duration is unclear. Since anxiety can be comorbid with depression in MS populations, it is relevant to establish its association in this setting. Finally, though anxiety usually increases in older age, research for this relationship in MS populations is inconclusive.
Design/Methods: The commonly used Hospital Anxiety and Depression Scale, was distributed once to patients with MS over a 3 month period to assess anxiety and depression scores. MS disease duration and age were confirmed by neurologists.
Results: Out of 160 patients with MS who completed the HADS, 19% reported abnormal anxiety, 14% reported borderline cases of anxiety, and 67% did not report anxiety. After following up on significant correlations, depression and younger age were related to higher anxiety levels, (R2=.35, F(4,144)=19.26, p<0.001). The standardized partial regression coefficients indicated 2 statistically significant predictors, depression (β=.55, p=<.001) and age (β=-.25, p=<.001).
Discussion: 33% of patients reported symptoms of anxiety, emphasizing the need to focus on treating anxiety, specifically, early in their disease course. Clinicians may also want to recognize that elevated depression scores predicted anxiety. Lastly, in our cohort, the younger population reported higher anxiety, demonstrating that progressive illnesses may affect anxiety levels in younger populations more. Since approximately one third of patients with MS expressed anxiety symptoms, it is important to incorporate this into treatment plans.
 Feinstein A, O’Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 2000; 5: 323-6.
 Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007; 13(1): 67-72.
 Dahl OP, Stordal E, Lydersen S, Midard R. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trondelag County, Norway. Mult Scler 2009; 15(12): 1495-1501.
 Vuger-Kovacic D, Gregurek R, Kovacic D, Vuger T, Kalenic, B. Relation between anxiety, depression and locus of control of patients with multiple sclerosis. Mult Scler 2007; 13(8): 1065-7.
 Donnchadha SO, Burke T, Bramham J, et al. Symptom overlap in anxiety and multiple sclerosis. Mult Scler 2013; 19(10): 1349-54.
 Anxiety and Depression Association of America (ADAA) Treatment [Internet] 2015. Available from: http://www.adaa. org/understanding-anxiety/depression/treatment. [accessed on 25 March 2015].
 Kazdin AE. Encyclopedia of Psychology. New York, NY: Oxford Univeristy Press 2000.
 Honarmand K, Feinstein A. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler 2009; 15(12): 1518-24.
 Wood B, van der Mei IAF, Ponsonby AL, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler 2013; 19(2): 217-24.
 Galeazzi GM, Ferrari S, Giaroli G, et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005; 26: 255-62.
 Nicholl CR, Lincoln NB, Francis VM, et al. Assessment of emotional problems in people with multiple sclerosis. Clin Rehabil 2001; 15: 657-68.
 Atkins L, Newby G, Primm J. Normative Data for the Hospital Anxiety and Depression Scales (HADS) in multiple sclerosis. Soc Care Neurodis 2012; 3(4): 172-8.
 Garfield AC, Lincoln NB. Factors affecting anxiety in multiple sclerosis. Disabil Rehabil 2012; 34(24): 2047-52.
 Beiske AG, Svensson E, Sandanger B, et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008; 15: 239-245. doi: 10.1111/f.1468-1331.2007.02041.x
 Lester K, Stepleman L, Hughes M. The association of illness severity, self-reported cognitive impairment, and perceived illness management with depression and anxiety in a multiple sclerosis clinic population. J Behav Med 2007; 30(2): 177-86.
 Janssens ACJW, van Doorn PA, de Boer JB, van der Meche FGA, Passchier J, Hintzen RQ. Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression, and distress of patients and partners. Acta Neurol Scandinavica 2003; 108: 389-95.
 Jones KH, Ford DV, Jones PA, et al. A Large-Scale Study of Anxiety and Depression in People with Multiple Sclerosis: A Survey via the Web Portal of the UK MS Register. PloS One 2012; 7(7): e41910.
 Brown RF, Valpiani EM, Tennant CC, et al. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother-T 2009; 82(1): 41-56.
 Giordano A, Granella F, Lugaresi A, et al. Anxiety and depression in multiple sclerosis patients around diagnosis. J Neurol Sci 2011; 307(1-2): 86-91.
 Hartoonian N, Beier ML, Turner AP, Day MA, Alschuler KN. Predictors of Anxiety in Multiple Sclerosis. Rehabil Psychol 2014; 60(1): 91-8.
 Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale score in persons with multiple sclerosis. BMC Neurol 2013; 13: 37-44.
 National Multiple Sclerosis Society (NMSS) What is MS? [Internet] 2015. Available from: http://www.nationalmssociety. org/What-is-MS. [accessed on 14 April 2015].